Jasper Therapeutics income statement data for the quarter ended Jun 2026. This income statement covers 26 quarters of results from Dec 2019 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 2.25M | 2.25M | 2.25M | 3.79M | 3.80M | 3.80M | 3.80M | 8.82M | 11.08M | 11.09M | 11.16M | 15.09M | 15.11M | 15.00M | 15.02M | 15.02M | 16.22M | 16.64M | 19.17M | 28.08M | ||||||
| Operating items | ||||||||||||||||||||||||||
| Research & DevelopmentR&D | 5.16M | 7.19M | 8.66M | 8.19M | 8.13M | 9.02M | 0.84M | 9.80M | 13.30M | 14.85M | 13.84M | 10.30M | 11.30M | 14.46M | 19.77M | 16.16M | 21.20M | 14.39M | 11.36M | |||||||
| Selling, General & AdministrativeSG&A | 3.26M | 2.89M | 3.42M | 4.59M | 3.83M | 3.69M | 4.46M | 4.14M | 4.53M | 4.51M | 3.89M | 4.77M | 4.70M | 5.43M | 5.51M | 5.64M | 5.88M | 4.78M | 4.48M | |||||||
| Restructuring CostsRestructuring | 0.13M | 0.08M | 0.10M | 0.56M | 0.48M | 0.47M | 6.11M | 6.21M | 9.76M | 15.77M | ||||||||||||||||
| Other Operating ExpensesOther Opex | -0.13M | -0.08M | -0.10M | -0.56M | -0.48M | -0.47M | 8.44M | -6.11M | -6.21M | -9.76M | -15.77M | |||||||||||||||
| Operating ExpensesOpex | 8.42M | 10.08M | 12.08M | 12.78M | 11.96M | 12.71M | 13.75M | 13.95M | 17.83M | 19.36M | 17.73M | 15.07M | 15.99M | 19.89M | 25.29M | 21.80M | 27.08M | 19.17M | 15.84M | |||||||
| Operating IncomeOp. Inc | -8.42M | -10.08M | -12.08M | -12.78M | -11.96M | -12.71M | -13.75M | -13.95M | -17.83M | -19.36M | -17.73M | -15.07M | -15.99M | -19.89M | -25.29M | -21.80M | -27.08M | -19.17M | -15.84M | |||||||
| EBIT | -8.42M | -10.08M | -12.08M | -12.78M | -11.96M | -12.71M | -13.75M | -13.95M | -17.83M | -19.36M | -17.73M | -15.07M | -15.99M | -19.89M | -25.29M | -21.80M | -27.08M | -19.17M | -15.84M | |||||||
| Non-operating items | ||||||||||||||||||||||||||
| Non Operating Interest Expenses | 0.07M | 0.11M | 0.02M | 0.04M | ||||||||||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.00M | 0.09M | 0.26M | 0.35M | 1.10M | 1.44M | 1.43M | 1.23M | 1.39M | 1.45M | 1.28M | 0.94M | 0.62M | 0.44M | 0.34M | 0.34M | ||||||||||
| Other Non Operating IncomeOther Non Op Inc. | 0.00M | 0.05M | -0.12M | -0.04M | -0.04M | -0.03M | 0.03M | -0.06M | -0.08M | -2.01M | -0.03M | |||||||||||||||
| Non Operating IncomeNon Op. Inc. | -0.31M | 1.75M | 1.82M | 1.14M | 1.34M | 1.41M | 1.25M | 0.96M | 0.56M | 0.35M | 0.43M | 6.74M | ||||||||||||||
| Net income details | ||||||||||||||||||||||||||
| EBT | -3.57M | -10.08M | -12.08M | -12.78M | -11.87M | -12.45M | -13.40M | -12.92M | -16.50M | -17.93M | -16.49M | -13.71M | -14.58M | -18.61M | -24.35M | -21.18M | -26.64M | -18.82M | -15.50M | |||||||
| Tax ProvisionsTaxes | ||||||||||||||||||||||||||
| Profit After TaxPAT | -8.41M | -3.41M | -6.16M | -2.21M | -10.40M | -11.90M | -13.20M | -14.30M | -16.10M | -17.54M | -16.62M | -13.73M | -14.60M | -18.64M | -24.35M | -21.24M | -26.72M | -18.74M | -9.10M | |||||||
| Income from Non-Controlling InterestsInc. Minority | -3.57M | |||||||||||||||||||||||||
| Income from Continuing OperationsIncome (Continuing) | -3.57M | -10.08M | -12.08M | -12.78M | -11.87M | -12.45M | -13.40M | -12.92M | -16.50M | -17.93M | -16.49M | -13.71M | -14.58M | -18.61M | -24.35M | -21.18M | -26.64M | -18.82M | -15.50M | |||||||
| Consolidated Net IncomeConsol Net Inc. | -3.57M | -10.08M | -12.08M | -12.78M | -11.87M | -12.45M | -13.40M | -12.92M | -16.50M | -17.93M | -16.49M | -13.71M | -14.58M | -18.61M | -24.35M | -21.18M | -26.64M | -18.82M | -15.50M | |||||||
| Income towards Parent CompanyParent Net Inc | -3.57M | 3.40M | -12.08M | -12.78M | -11.87M | 11.90M | -13.40M | -12.92M | -16.50M | -17.93M | -16.49M | -13.71M | -14.58M | -18.61M | -24.35M | -21.18M | -26.64M | -18.82M | -15.50M | |||||||
| Net Income towards Common StockholdersNet Income | -3.57M | -3.41M | -9.06M | -2.21M | -11.87M | 11.90M | -13.40M | -12.92M | -16.50M | -17.93M | -16.49M | -13.73M | -14.58M | -18.61M | -24.35M | -21.24M | -26.72M | -18.82M | -15.50M | |||||||
| Additional items | ||||||||||||||||||||||||||
| EPS (Basic) | -2.86 | -6.87 | -7.95 | -0.61 | -3.26 | 3.25 | -3.67 | -1.47 | -1.51 | -1.75 | -1.58 | -1.03 | -0.97 | -1.24 | -1.67 | -1.41 | -1.74 | -1.13 | -0.81 | |||||||
| EPS (Diluted) | -6.87 | -7.95 | -0.61 | -3.26 | 3.25 | -3.67 | -1.47 | -1.51 | -1.75 | -1.58 | -1.03 | -0.97 | -1.24 | -1.67 | -1.41 | -1.74 | -1.13 | -0.81 | ||||||||
| Shares Outstanding | 1.25M | 0.50M | 1.14M | 3.63M | 3.64M | 3.66M | 3.65M | 8.82M | 10.92M | 10.23M | 10.44M | 13.33M | 14.99M | 15.00M | 14.58M | 15.02M | 15.33M | 16.64M | 19.17M | 28.70M | ||||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 0.50M | 1.14M | 3.63M | 3.64M | 3.66M | 3.65M | 8.82M | 10.92M | 10.23M | 10.44M | 13.33M | 14.99M | 15.00M | 14.58M | 15.02M | 15.33M | 16.64M | 19.17M | 28.70M | |||||||
| EBITDA | -8.42M | -10.08M | -12.08M | -12.78M | -11.96M | -12.71M | -13.75M | -13.95M | -17.83M | -19.36M | -17.73M | -15.07M | -15.99M | -19.89M | -25.29M | -21.80M | -27.08M | -19.17M | -15.84M | |||||||
| Interest ExpensesInt Expense | 0.07M | 0.11M | 0.02M | 0.04M | ||||||||||||||||||||||
| Tax Rate |